Sucampo Pharmaceuticals, Inc. is a U.S.-based biopharmaceutical company focused on the development and commercialization of drugs targeting gastrointestinal disorders. Its flagship product, AMITIZA (lubiprostone), was approved by the U.S. FDA in 2006 for chronic idiopathic constipation in adults.
Previously marketed in partnership with Takeda, the collaboration ended in March 2024, after which AMITIZA ceased to be sold or marketed by Takeda.
Jury awarded USD 884,943,990 in single damages in AMITIZA antitrust trial; wholesaler/retailer sums subject to trebling. Will appeal, assess provision and revise FY2025 filings; minimal FY2026 impact.
